Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.87 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL651958 | 1.00 | CCR1 (0.87) | CCR1CHRM2CCR5HRH1TP53 | |
| SCHEMBL10288018 | 1.00 | CCR1 (0.87) | CCR1CHRM2CCR5HRH1TP53 | |
| SCHEMBL16312671 | 0.95 | CCR1 (0.83) | CCR1CHRM2CCR5HRH1TP53 | |
| SCHEMBL653493 | 0.93 | CCR1 (1.00) | CCR1CHRM2CCR5HRH1TP53 | |
| SCHEMBL438488 | 0.93 | CCR1 (1.00) | CCR1CHRM2CCR5HRH1TP53 | |
| SCHEMBL438487 | 0.93 | CCR1 (1.00) | CCR1CHRM2CCR5HRH1TP53 | |
| SCHEMBL13620905 | 0.93 | CCR1 (1.00) | CCR1CHRM2CCR5HRH1TP53 | |
| SCHEMBL438265 | 0.93 | CCR1 (1.00) | CCR1CHRM2CCR5HRH1TP53 | |
| SCHEMBL653494 | 0.93 | CCR1 (1.00) | CCR1CHRM2CCR5HRH1TP53 | |
| SCHEMBL403450 | 0.93 | CCR1 (1.00) | CCR1CHRM2CCR5HRH1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2286811-A1 | Chemokine receptor antagonists and methods of use thereof | Millennium Pharmaceuticals, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| US-7541365-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | THPO, NFATC1, HPGDS | CCR1 19/4885CHRM2 615/4885CCR5 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.